Navigation Links
Genprex Announces New Patent Issuance in Japan
Date:10/18/2011

AUSTIN, Texas, Oct. 18, 2011 /PRNewswire/ -- A new patent covering tumor suppression technologies, including the company's lead product candidate Oncoprex™, was recently awarded to The University of Texas System by the Japan Patent Office. Patent number 4813746 pertains to the discovery that chromosome 3p21.3 genes act as cancer suppressors. The family of tumor suppressors include TUSC2, also known as FUS1, the anti-cancer agent in Oncoprex therapy which is undergoing clinical evaluation for lung cancer patients in the U.S.

"Japan represents an important clinical population," stated Chief Operating and Financial Officer Greg Heinlein. "We intend to include Japanese collaborators in our development and commercialization plans and have begun to establish key relations within the region, including appointments of leading oncology experts to our Medical and Scientific Advisory Board."

Genprex controls a portfolio of biomedical technologies including targeted molecular therapeutics for cancer and other diseases. The novel technologies, including those licensed exclusively from The University of Texas MD Anderson Cancer Center, are protected by 15 issued patents and 9 pending applications in major market areas. These broadly applicable technologies have been the subject of more than 20 peer-reviewed scientific publications in the fields of cancer, genomics and molecular biology.

About Oncoprex™Oncoprex is a nanomolecular therapy harnessing the TUSC2 tumor suppressor. TUSC2 defects are associated with most major cancers and >85% of lung cancers. Intravenous Oncoprex induces apoptosis or programmed cell death in cancer cells and controls cell signaling and inflammation to fight cancer along universal cancer pathways. In phase I clinical testing of Stage IV lung cancer patients, Oncoprex monotherapy was well tolerated and demonstrated clinically significant anti-cancer activity in primary lung tumors and metastatic tumors, including liver and pancreas. A phase II clinical trial evaluating Oncoprex in combination with Tarceva® (erlotinib) is planned for 2012. The trial will enroll lung cancer patients without the EGFR mutation and patients with EGFR mutations who have become unresponsive to erlotinib.

About GenprexGenprex, Inc. is a privately held, clinical-stage biopharmaceutical company developing nanomolecular therapies that control universal cancer pathways to unlock the unrealized potential of a variety of targeted cancer therapies. For more information about Genprex click here. Tarceva® is a registered trademark of the Roche Group, including Genentech and Chugai, and of Astellas Pharma.Contact:

Greg HeinleinPhone:

512-597-5900www.genprex.com
'/>"/>

SOURCE Genprex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development
2. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
3. Hologic Announces Jury Verdict in Patent Infringement Suit
4. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
5. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
6. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
7. Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
8. Bend Research Announces Schedule of Events at 2011 AAPS Annual Meeting and Exposition
9. Pacira Pharmaceuticals, Inc. Announces Key EXPAREL™ Data to be Presented at American College of Surgeons 97th Annual Clinical Congress
10. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
11. Express Scripts Announces Third Quarter 2011 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ... Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) expired ... Time). As previously announced on May 31, ... merger agreement under which Jazz Pharmaceuticals has commenced a ...
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)...   Bay Area Lyme Foundation , collaborating ... for Tick Borne Illness , Harvard Medical School ... Medicine, University of California, Berkeley, and the Veterans ... finalists of Lyme Innovation , the first ... scientists, clinicians, researchers, entrepreneurs, and investors from several ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 , ... ... mental health professionals, announced today its affiliation with Tennessee Counseling Association. ... to the network of the Tennessee Counseling Association, adding exclusive benefits and promotional ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
Breaking Medicine News(10 mins):